Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610267 · ClinicalTrials.gov registry record
Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair
A clinical trial of Ventral Hernia, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- 28
- Enrollment target
- 1
- Study location
NCT05610267: Completed study of Ventral Hernia, sponsored by Integra LifeSciences Corporation.
NCT05610267 is a study of Ventral Hernia that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 28 participants, below the 141-participant average among 18 other Ventral Hernia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05610267, a study of Ventral Hernia, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect additional safety data and demonstrate the performance of Integra Gentrix® Surgical Matrix for reinforcement of ventral hernia repairs.
Primary Outcome
Percentage of subjects with a post-operative complications requiring procedural intervention within 90 days post index procedure
Conditions Studied
Interventions
- DEVICE Retrospective chart review
Study Locations (1)
Florida
- Surgical Healing Arts Center - Fort Myers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-11-22 |
| Est. Completion | 2022-12-28 |
What the finished NCT05610267 record still lists
NCT05610267 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 141-participant average among 18 other Ventral Hernia trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Ventral Hernia appearing as the primary indexed condition, and to 1 intervention - of which Retrospective chart review is the first listed.
NCT05610267 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05610267 about?
NCT05610267 is a clinical study titled "Gentrix® Surgical Matrix for Soft Tissue Reinforcement in Ventral Hernia Repair". The purpose of this study is to collect additional safety data and demonstrate the performance of Integra Gentrix® Surgical Matrix for reinforcement of ventral hernia repairs.
What is the current status of trial NCT05610267?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2022-11-22. Estimated completion is 2022-12-28.
What conditions does trial NCT05610267 study?
This clinical trial studies the following conditions: Ventral Hernia.
What interventions are being tested in trial NCT05610267?
The interventions under investigation include: Retrospective chart review (DEVICE).
Who is sponsoring clinical trial NCT05610267?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610267 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ventral Hernia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05610267's enrollment target sits among peer trials
28 19th of 18 the lowest of 18 other Ventral Hernia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ventral Hernia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AFFIX: Post-market Study of MaxTack™ Motorized Fixation Device in Subjects Undergoing Ventral Hernia Repair
RECRUITING · NA
-
Robotic Versus Open Ventral Hernia Repair
RECRUITING · NA
-
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair
RECRUITING · Phase 2
-
Clinical Investigation of the da Vinci Surgical System
ACTIVE NOT RECRUITING · NA
-
Post-operative Pain Control-TAP Block Using Exparel vs. Marcaine for Hernia Repairs
ACTIVE NOT RECRUITING · Early Phase 1
-
Methocarbamol in Ventral and Inguinal HR
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI